Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 19 04:00PM ET
1.24
Dollar change
-0.04
Percentage change
-3.12
%
CategoryGlobal or ExUS Equities - Industry Sector Asset TypeEquities (Stocks) TagsGlobal Return% 1Y-33.83% Shs Outstand Perf Week-9.49%
SponsorAdvisor Shares ETF Type Tagsequity Return% 3Y- Total Holdings26 Perf Month-15.07%
Fund Family Bond Type Tagshealthcare Return% 5Y- AUM6.89M Perf Quarter-9.49%
Index- Average Maturity Tagspharmaceutical Return% 10Y NAV% Perf Half Y-15.63%
Index Weighting Commodity Type Tagsmedical Return% SI NAV/sh Perf Year-33.96%
Active/Passive Quant Type Tags- Flows% 1M11.07% 52W Range1.25 - 2.25 Perf YTD-10.79%
Dividend TTM0.00 (0.27%) ESG Type Tags- Flows% 3M23.88% 52W High-44.86% Beta0.99
Dividend Ex-DateSep 25, 2023 Dividend Type Sector/Theme Flows% YTD27.33% 52W Low-0.80% ATR (14)0.07
Expense0.99% Structure Type Region Flows% 1Y RSI (14)27.79 Volatility4.73% 4.28%
Option/ShortYes / Yes Growth/Value Dev/Emerg Flows% 3Y Rel Volume1.26 Prev Close1.28
Inverse/Leveraged Market Cap Currency Flows% 5Y Avg Volume72.91K Price1.24
SMA20-13.95% SMA50-15.78% SMA200-20.44% Trades Volume91,619 Change-3.12%
AdvisorShares Psychedelics ETF seeks long-term capital appreciation. The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.